
    
      The study is a randomized, double-blind, placebo-controlled, Phase 2/3 trial to evaluate the
      safety and efficacy of DSTAT in adults with severe COVID-19 who are at high risk of
      respiratory failure. Eligible subjects will be those with confirmed COVID-19 who require
      hospitalization and supplemental oxygen therapy.
    
  